Scibase (SCIB.ST)

Executive Summary

SciBase is a German medical technology company pioneering augmented intelligence solutions for dermatological diagnostics. Its core product, the Nevisense platform, combines Electrical Impedance Spectroscopy (EIS) with artificial intelligence to improve diagnostic accuracy for skin cancer and skin barrier function. Founded in 2018 and headquartered in Berlin, the company addresses a critical need in dermatology: the high rate of misdiagnosis in skin cancer detection. By providing point-of-care, non-invasive diagnostics, SciBase aims to reduce unnecessary biopsies and improve patient outcomes. The global skin cancer diagnostics market is growing rapidly, driven by rising incidence rates and increasing adoption of AI-based tools, positioning SciBase for significant expansion. The company has made substantial progress in commercializing Nevisense, with regulatory approvals in Europe and a growing body of clinical evidence. Its valuation of approximately $470 million reflects investor confidence in its technology and market potential. Key upcoming milestones include expanded regulatory clearances for additional indications, such as basal cell carcinoma and melanoma, and potential strategic partnerships to broaden market access. However, the company remains pre-revenue on a commercial scale and faces competition from established diagnostic modalities. Successful execution of its regulatory and commercial strategy will be critical to achieving long-term growth.

Upcoming Catalysts (preview)

• Q1 2027FDA 510(k) clearance for Nevisense for melanoma detection70% success
• Q3 2026CE mark expansion for additional skin cancer indications (e.g., basal cell carcinoma)80% success
• Q2 2027Strategic partnership with a major dermatology network or pharmaceutical company60% success